ALACHUA, Fla., Nov. 28, 2018 /PRNewswire/ -- Brammer Bio ("Brammer"), a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO), was recognized by the Greater Gainesville Chamber of Commerce as the Manufacturing Company of the Year at its recent 2018 Business of the Year awards program. Brammer was also named one of the top-three finalists for the BioScience Company of the Year award. The Greater Gainesville Chamber of Commerce's mission is to facilitate economic opportunity, business success and community progress. The awards assess these factors, as well as training and development opportunities for employees and company culture. The awards are judged by an independent group and the winners are acclaimed leaders in their specific industries.
"We are honored to be recognized as the recipient of this award," said Mark Bamforth, President and CEO of Brammer Bio. "This is an opportunity to celebrate our talented team and recognize our commitment to employee development and community involvement. It is a testament to our team's dedication over the last twelve years to helping our clients succeed in delivering cutting edge therapies to their patients in need, and to the Greater Gainesville area's commitment to fostering the long-term growth of the state's manufacturing and bioscience sectors. We are especially proud to be among the strong group of recipients and nominees recognized by the Business of the Year awards."
Brammer has more than doubled its diverse workforce to 250, with over 30 percent minorities and a strong focus on gender balance through a Women in Leadership program and 50:50 gender ratio throughout the organization, including the leadership team. Founder and CSO Richard Snyder and Vice President and Alachua Site Head Larry Pitcher accepted the award at a recent ceremony and commented, "We are committed to supporting our employees through professional development, growth opportunities and an educational assistance program, as well as supporting our employees' charitable giving through a matching gift program."
"Brammer Bio is a very deserving recipient of the Manufacturing Company of the Year award," said Eric Godet, Interim President/CEO of the Greater Gainesville Chamber. "Having spun out of the University of Florida in 2015 and choosing to grow right here in Alachua County, Brammer Bio embodies the essence of Greater Gainesville. By continuing to expand and invest in both talent and facilities here, Brammer Bio is adding to our region's ever-growing biotechnology cluster."
Brammer maintains a strong relationship with the University of Florida (UF), and approximately 25 percent of the team are UF graduates.
Brammer specializes in the development of processes and analytics and the manufacture of viral vectors for use in treating genetic and acquired diseases. With more than 12 years of experience in Alachua, Fla., our highly skilled team has managed over 100 client projects delivering clinical materials for first-in-human gene therapy trials to accelerate our clients' products from the laboratory to patients.
Brammer also continues to expand its facilities and currently occupies an 80,000 square-foot three-building campus in Alachua comprised of a process and analytical development facility, adjacent to a CGMP clinical manufacturing operation and a nearby warehouse and office building. The CGMP facility accommodates spatially segregated viral vector processing in dedicated production suites that allows concurrent manufacturing.
Brammer is proud to support local charities in our community through financial support and participation in local events. We recognize the importance and benevolence of charitable nonprofit organizations and are happy to partner with organizations whose missions are aligned with ours. Our employees are active in organizations ranging from the Florida Public Relations Association to BioFlorida to the current class of Leadership Gainesville, and our executive team serves on several non-profit boards.
About Brammer Bio
Brammer Bio provides clinical and commercial supply of vectors for in vivo gene therapy and ex vivo modified-cell based therapy, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders. For more information, please visit www.brammerbio.com.
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com
SOURCE Brammer Bio